<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03695380</url>
  </required_header>
  <id_info>
    <org_study_id>YO40482</org_study_id>
    <secondary_id>2018-000631-27</secondary_id>
    <nct_id>NCT03695380</nct_id>
  </id_info>
  <brief_title>A Clinical Study of Cobimetinib Administered in Combination With Niraparib, With or Without Atezolizumab to Patients With Advanced Platinum-sensitive Ovarian Cancer</brief_title>
  <official_title>A Phase Ib Study of Cobimetinib Administered in Combination With Niraparib, With or Without Atezolizumab, To Patients With Advanced Platinum-sensitive Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will include a safety run-in phase (Stage 1) and a randomization phase (Stage 2).&#xD;
&#xD;
      The purpose of Stage 1 is to evaluate the safety of cobimetinib when administered in&#xD;
      combination with niraparib (Cohort 1) and cobimetinib with niraparib plus atezolizumab&#xD;
      (Cohort 2).&#xD;
&#xD;
      Stage 1 will enable patient enrollment in the randomized phase of the study (Stage 2) with&#xD;
      both regimens at the recommended dose levels from Stage 1.&#xD;
&#xD;
      Stage 2 is a randomized, dose-expansion phase, evaluating clinical outcomes in patients with&#xD;
      advanced platinum-sensitive ovarian cancer.&#xD;
&#xD;
      All patients will continue to receive study treatment until disease progression (according to&#xD;
      &quot;Response Evaluation Criteria in Solid Tumors&quot; (RECIST), Version 1.1, unacceptable toxicity,&#xD;
      death, or patient or investigator decision to withdraw, whichever occurs first.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 9, 2019</start_date>
  <completion_date type="Anticipated">April 28, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 28, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients reporting Adverse Events (AEs)</measure>
    <time_frame>From baseline up to 48 months</time_frame>
    <description>The safety profiles of Cobimetinib plus Niraparib and Cobimetinib plus Niraparib plus Atezolizumab will be evaluated in terms of number of patients reporting serious and non-serious AEs with severity graded according to National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI - CTCAE v5.0)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in targeted clinical laboratory test results</measure>
    <time_frame>From baseline up to 48 months</time_frame>
    <description>The safety profiles of Cobimetinib plus Niraparib and Cobimetinib plus Niraparib plus Atezolizumabwill be evaluated in terms of number of patients reporting change from baseline in targeted clinical laboratory test results.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Investigator-assessed confirmed objective response rate (ORR)</measure>
    <time_frame>From baseline up to 48 months</time_frame>
    <description>The efficacy profiles of Cobimetinib plus Niraparib and Cobimetinib plus Niraparib plus Atezolizumab will be evaluated in terms of investigator-assessed confirmed ORR, as determined using RECIST v1.1 in the Intention To Treat (ITT) population and in molecularly defined subgroups by loss of heterozygosity (LOH) status.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>From Baseline up to 48 months</time_frame>
    <description>The efficacy profiles of Cobimetinib plus Niraparib and Cobimetinib plus Niraparib plus Atezolizumab will be evaluated in terms of PFS after randomization, defined as the time from randomization to the first occurrence of disease progression or relapse, as determined by the investigator using RECIST v1.1, or death from any cause during the study, whichever occurs first, in the ITT population and in the molecularly defined subgroups by LOH status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>From baseline up to 48 months</time_frame>
    <description>The efficacy profiles of Cobimetinib plus Niraparib and Cobimetinib plus Niraparib plus Atezolizumab will be evaluated in terms of DOR, defined for patients achieving at least one confirmed Partial Response (PR), which is measured from the first observation of a Complete Response (CR) or a PR to the time of disease progression in the ITT population and in the molecularly defined subgroups by LOH status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>From baseline up to 48 months</time_frame>
    <description>The efficacy profiles of Cobimetinib plus Niraparib and Cobimetinib plus Niraparib plus Atezolizumab will be evaluated in terms of OS after randomization, defined as the time from randomization until death from any cause in the ITT population and in the molecularly defined subgroups by LOH status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of cobimetinib and niraparib</measure>
    <time_frame>Arm A: Day 15 of Cycle 1 and 2 - Arm B: Day 15 of Cycle 1</time_frame>
    <description>The Pharmacokinetic (PK) profile of cobimetinib plus niraparib is evaluated in terms of Plasma concentration at specified timepoints.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration of atezolizumab</measure>
    <time_frame>Day 1 of Cycle 1, 2 and 3 and at treatment discontinuation visit, up to 48 months</time_frame>
    <description>The PK profile of cobimetinib plus niraparib plus atezolizumab will be evaluated in terms of Serum concentration of atezolizumab at specified timepoints (Arm B only).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with Anti-Drug Antibodies (ADA)</measure>
    <time_frame>Day 1 of Cycle 1, 2 and 3 and at treatment discontinuation visit, up to 48 months</time_frame>
    <description>The immunogenicity profile of Atezolizumab is evaluated in terms of number of patients with ADA at baseline and during the study.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>OVARIAN CANCER</condition>
  <arm_group>
    <arm_group_label>Arm A: Cobimetinib - Niraparib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stage 2 - Patients will receive cobimetinib PO QD on Days 1-21 (21/7 schedule) in combination with niraparib PO QD on Days 1-28 of each 28-day cycle at the established dose for the doublet regimen in Stage 1, Cohort 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: Cobimetinib - Niraparib - Atezolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stage 2 - Patients will receive cobimetinib PO QD on Days 1-21 (21/7 schedule) in combination with niraparib QD on Days 1-28 at the established doses for the triplet regimen in Stage 1,Cohort 2 plus atezolizumab by IV infusion at the fixed dose of 840 mg on Days 1 and 15 (+/-3 days) of each 28-day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1 - Cobimetinib - Niraparib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stage 1 - Patients in Cohort 1 will be treated with cobimetinib plus niraparib.&#xD;
Cobimetinib: Patients will receive a starting dose of 60 mg by mouth (PO) daily (QD) on Days 1-21 of each 28-day cycle.&#xD;
Niraparib: Patients will receive a starting dose of 200 mg of niraparib PO QD on Days 1-28 of each 28-day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 - Cobimetinib - Niraparib - Atezolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stage 1 - Patients in Cohort 2 will be treated with cobimetinib plus niraparib and atezolizumab.&#xD;
Cobimetinib: Patients will receive a starting dose of 60 mg by mouth (PO) daily (QD) on Days 1-21 of each 28-day cycle.&#xD;
Niraparib: Patients will receive a starting dose of 200 mg of niraparib PO QD on Days 1-28 of each 28-day cycle.&#xD;
Atezolizumab: Patients will also receive atezolizumab administered as an IV infusion at a fixed dose of 840 mg on Days 1 and 15 (+/-3 days) of each 28-day cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cobimetinib</intervention_name>
    <description>Cobimetinib will be administered at a starting dose of 60 mg by mouth (PO) daily (QD) on Days 1-21 of each 28-day cycle (Stage 1) and PO QD on Days 1-21 (21/7 schedule) at the established dose for the doublet regimen in Stage 1 (Stage 2).</description>
    <arm_group_label>Arm A: Cobimetinib - Niraparib</arm_group_label>
    <arm_group_label>Arm B: Cobimetinib - Niraparib - Atezolizumab</arm_group_label>
    <arm_group_label>Cohort 1 - Cobimetinib - Niraparib</arm_group_label>
    <arm_group_label>Cohort 2 - Cobimetinib - Niraparib - Atezolizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Niraparib</intervention_name>
    <description>Niraparib will be administered at a starting dose of 200 mg of niraparib PO QD on Days 1-28 of each 28-day cycle (Stage 1) and PO QD on Days 1-28 of each 28-day cycle at the established dose for the doublet regimen in Stage 1 (Stage 2).</description>
    <arm_group_label>Arm A: Cobimetinib - Niraparib</arm_group_label>
    <arm_group_label>Arm B: Cobimetinib - Niraparib - Atezolizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atezolizumab</intervention_name>
    <description>Atezolizumab will be administered by IV infusion at the fixed dose of 840 mg on Days 1 and 15 (+/-3 days) of each 28-day cycle (Stages 1 and 2).</description>
    <arm_group_label>Arm B: Cobimetinib - Niraparib - Atezolizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Ability to comply with the study protocol, in the investigator's judgment&#xD;
&#xD;
          -  Willingness and ability to comply with scheduled visits, treatment plans, laboratory&#xD;
             tests, and other study procedures, including the completion of patient-reported&#xD;
             outcome questionnaires&#xD;
&#xD;
          -  Histological diagnosis of high-grade serous or Grade 2 or Grade 3 endometrioid&#xD;
             epithelial ovarian, fallopian tube, or primary peritoneal cancer&#xD;
&#xD;
          -  Previous treatment with a minimum of one and a maximum of two prior platinum based&#xD;
             treatment regimens&#xD;
&#xD;
          -  Platinum-sensitive disease&#xD;
&#xD;
          -  Availability of tumor biopsy tissue prior to first dose of study treatment with&#xD;
             confirmation by the central laboratory that the sample is not only of adequate quality&#xD;
             but also assignable to a molecularly defined subgroup based on breast cancer&#xD;
             susceptibility gene (BRCA) and loss of heterozygosity (LOH) status&#xD;
&#xD;
          -  Measurable disease, as defined by Response Evaluation Criteria in Solid Tumors,&#xD;
             version 1.1 (RECIST v1.1)&#xD;
&#xD;
          -  Adequate hematologic and organ function&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group Performance Status of 0 or 1&#xD;
&#xD;
          -  Life expectancy of at least 12 weeks&#xD;
&#xD;
          -  Resolved or stabilized toxicities resulting from previous therapy to Grade 1&#xD;
&#xD;
          -  Negative HIV test at screening&#xD;
&#xD;
          -  Negative hepatitis B surface antigen and total hepatitis B core antibody (HBcAb) test,&#xD;
             or positive total HBcAb test followed by quantitative hepatitis B virus (HBV) DNA &lt;&#xD;
             500 IU/mL test at screening&#xD;
&#xD;
          -  Negative hepatitis C virus (HCV) antibody test, or positive HCV antibody test followed&#xD;
             by a negative HCV RNA test at screening&#xD;
&#xD;
          -  For women of childbearing potential: Women must remain abstinent or use two&#xD;
             contraceptive methods with a failure rate of &lt;1% per year during the treatment period&#xD;
             and for at least 3 months after the last dose of cobimetinib, 6 months after the last&#xD;
             dose of niraparib, and 5 months after the last dose of atezolizumab. Women must&#xD;
             refrain from donating eggs during this same period&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Prior treatment with mitogen-activated protein kinase inhibitor, polyadenosine&#xD;
             diphosphate-ribose polymerase inhibitor, or immune checkpoint inhibitor therapies&#xD;
&#xD;
          -  Prior chemotherapy, hormonal therapy, radiotherapy, antibody therapy, or other&#xD;
             immunotherapy, gene therapy, vaccine therapy, or treatment with experimental drugs&#xD;
             within 14 days prior to first dose of study treatment&#xD;
&#xD;
          -  Treatment with systemic immunostimulatory agents within 28 days or 5 half-lives of the&#xD;
             drug prior to initiation of study treatment&#xD;
&#xD;
          -  Treatment with systemic immunosuppressive medication 14 days prior to initiation of&#xD;
             study treatment, or anticipation of need for systemic immunosuppressive medication&#xD;
             during the study&#xD;
&#xD;
          -  History of other malignancy that could affect compliance with the protocol or&#xD;
             interpretation of results, or known to have potentially fatal outcome&#xD;
&#xD;
          -  Symptomatic and/or untreated central nervous system metastases&#xD;
&#xD;
          -  Surgical procedure, significant traumatic injury within 14 days prior to enrollment,&#xD;
             or anticipation of need for major surgical procedure during the study&#xD;
&#xD;
          -  Minor surgical procedure within 3 days&#xD;
&#xD;
          -  History or evidence of retinal pathology on ophthalmic examination&#xD;
&#xD;
          -  Left ventricular ejection fraction below institutional lower limit of normal&#xD;
&#xD;
          -  History of clinically significant cardiovascular dysfunction&#xD;
&#xD;
          -  History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced&#xD;
             pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on the&#xD;
             screening chest computed tomography scan&#xD;
&#xD;
          -  History or evidence of inherited bleeding diathesis or significant coagulopathy at&#xD;
             risk for bleeding&#xD;
&#xD;
          -  History of severe allergic, anaphylactic, or other hypersensitivity reactions to&#xD;
             chimeric or humanized antibodies or fusion proteins, or to any component of the&#xD;
             atezolizumab formulation&#xD;
&#xD;
          -  Known allergy or hypersensitivity to any component of the cobimetinib or niraparib&#xD;
             formulation&#xD;
&#xD;
          -  Active or history of autoimmune disease or immune deficiency including, but not&#xD;
             limited to, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus&#xD;
             erythematosus, rheumatoid arthritis, inflammatory bowel disease, anti-phospholipid&#xD;
             antibody syndrome, Wegener granulomatosis, Sjögren syndrome, Guillain-Barre syndrome,&#xD;
             or multiple sclerosis&#xD;
&#xD;
          -  Uncontrolled serious medical or psychiatric illness&#xD;
&#xD;
          -  History of malabsorption or other condition that would interfere with absorption of&#xD;
             oral study drugs, including preexisting duodenal stent or ongoing intestinal&#xD;
             obstruction&#xD;
&#xD;
          -  Active tuberculosis&#xD;
&#xD;
          -  Severe infection within 14 days prior to initiation of study treatment, including, but&#xD;
             not limited to, hospitalization for complications of infection, bacteremia, or severe&#xD;
             pneumonia&#xD;
&#xD;
          -  Treatment with therapeutic oral or IV antibiotics within 7 days prior to initiation of&#xD;
             study treatment&#xD;
&#xD;
          -  Treatment with a live, attenuated influenza vaccine within 28 days prior to study&#xD;
             treatment initiation, at any time during the study, and for at least 5 months after&#xD;
             the last dose of study drug&#xD;
&#xD;
          -  Any other disease, metabolic dysfunction, physical examination finding, or clinical&#xD;
             laboratory finding that contraindicates the use of an investigational drug, may affect&#xD;
             the interpretation of the results, or may render the patient at high risk from&#xD;
             treatment complications&#xD;
&#xD;
          -  Previous treatment with strong CYP3A inhibitors (such as ketoconazole and&#xD;
             clarithromycin), strong CYP3A inducers (such as carbamazepine and phenytoin), and&#xD;
             moderate CYP3A inducers (such as efavirenz, modafinil) within 7 days prior to the&#xD;
             initiation of study treatment or with ongoing requirements for these medications&#xD;
&#xD;
          -  Pregnancy or breastfeeding, or intention to become pregnant during the study&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Reference Study ID Number: YO40482 https://forpatients.roche.com/</last_name>
    <phone>888-662-6728 (U.S. and Canada)</phone>
    <email>global-roche-genentech-trials@gene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Arizona Cancer Center, North</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85719</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Moores Cancer Center at UC San Diego Health</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sutter Health</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic-Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Florida Hospital Cancer Institute; Clinical Research Department</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical College of Georgia; Obstetrics &amp; Gynecolog</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912-3335</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Sidney Kimmel Comprehensive Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine; Dept of Medicine/Div of Medical Oncology</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Stephenson Cancer Center Investigational Pharmacy</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Jordan Center for Gynecologic Cancers</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology; Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>VCU Massey Cancer Center, Dalton Oncology Clinic</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin; Department of Obstetrics and Gynecology</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Bergonié Centre Régional de Lutte Contre Le Cancer de Bordeaux Et Sud Ouest</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Hopital Europeen Georges Pompidou; Service D'Oncologie Medicale</name>
      <address>
        <city>Paris</city>
        <zip>75908</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre Benite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Tumori Fondazione G. Pascale</name>
      <address>
        <city>Napoli</city>
        <state>Campania</state>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fondazione Policlinico Universitario &quot;A. Gemelli&quot;; Unità di Fase 1: Unità di Farmacologia Clinica</name>
      <address>
        <city>Rome</city>
        <state>Lazio</state>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale dei Tumori; Divisione Oncologia Chirurgica e Ginecologica</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Istituto Europeo di Oncologia; Svil. Nuovi Farmaci per Terapie Innovative</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro Oncologico de Galicia COG; Medical Oncology</name>
      <address>
        <city>A Coruna</city>
        <state>LA Coruña</state>
        <zip>15009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall dHebron; Oncology</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>ICO Girona</name>
      <address>
        <city>Girona</city>
        <zip>17007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Jaen-Hospital Universitario Medico Quirurgico; Servicio de Oncologia</name>
      <address>
        <city>Jaen</city>
        <zip>23007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinica Universidad de Navarra Madrid; Servicio de Oncología</name>
      <address>
        <city>Madrid</city>
        <zip>28027</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Hospital Ramon y Cajal; Servicio de Oncologia</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico San Carlos; Servicio de Oncologia</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Valencia; Servicio de Oncología</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 30, 2018</study_first_submitted>
  <study_first_submitted_qc>October 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 4, 2018</study_first_posted>
  <last_update_submitted>November 10, 2021</last_update_submitted>
  <last_update_submitted_qc>November 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atezolizumab</mesh_term>
    <mesh_term>Niraparib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

